Advertisement

The Latest

DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has finished enrolling patients in its Japanese study of  IDCT, an allogeneic, injectable disc cell therapy for lumbar disc degeneration.

Spine surgeons investing in surgery centers have the potential to realize significant profit in the coming years as procedures continue to shift from inpatient to outpatient settings.

DJO acquired MedShape, in its latest push into the foot and ankle space.

Advertisement